申请人:Mitsubishi Kasei Corporation
公开号:US05153217A1
公开(公告)日:1992-10-06
A novel pyrrolealdehyde derivative represented by the following formula (I): ##STR1## wherein R represents C.sub.10 -C.sub.16 alkyl unsubstituted or substituted by at least one substituent selected from the group consisting of halo, hydroxy, amino, carbamoyl, C.sub.1 -C.sub.5 alkylamino, C.sub.2 -C.sub.6 dialkylamino, C.sub.2 -C.sub.6 acylamino, C.sub.1 -C.sub.5 alkylthio, mercapto, C.sub.2 -C.sub.6 acyloxy, carbamoyloxy, C.sub.6 -C.sub.12 aryl and C.sub.3 -C.sub.7 cycloalkyl; or C.sub.10 -C.sub.16 alkenyl having at least one vinyl, and a pharmaceutically acceptable salt thereof are provided. The compounds are highly effective in reducing the level of triglyceride and cholesterol in serum, and useful as an active ingredient of a pharmaceutical composition for treating hyperlipemia and arteriosclerosis.
提供如下公式(I)所代表的一种新型吡咯甲醛衍生物:##STR1## 其中R代表未取代或取代的C.sub.10-C.sub.16烷基,所述取代至少包括来自卤素、羟基、氨基、氨基甲酰、C.sub.1-C.sub.5烷基氨基、C.sub.2-C.sub.6二烷基氨基、C.sub.2-C.sub.6酰胺基、C.sub.1-C.sub.5烷基硫醚、巯基、C.sub.2-C.sub.6酰氧基、氨基甲酰氧基、C.sub.6-C.sub.12芳基和C.sub.3-C.sub.7环烷基的至少一种取代基;或至少含有一个乙烯基的C.sub.10-C.sub.16烯基,以及其在药学上可接受的盐。这些化合物对降低血清中甘油三酯和胆固醇水平非常有效,并可用作治疗高脂血症和动脉硬化的药物组合物的活性成分。